Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsThese were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.
As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.
1.
By acquiring T3 Pharma, a leader in bacterial cancer treatment, Boehringer Ingelheim broadens its offering in immunooncology.
2.
Study links persistent fatigue in breast cancer survivors to increased inflammation
3.
The combination of nitedanib and prednisone reduces exacerbations of pulmonary diseases in radiative pneumonitis
4.
Metastatic Cancer 'Thrivers'; Celebrity Cancer Diagnoses; 'Would He Have Lived?'
5.
Research finds low uptake of supportive care at the end-of-life for patients with advanced cancer
1.
Exploring The Causes and Consequences of Low Transferrin Saturation
2.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
3.
Carboplatin Treatment: What You Need to Know About Side Effects and Efficacy
4.
Mastering Surgical Oncology: Education, Certification, Trials, and Therapy Insights
5.
What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part III
4.
Navigating the Complexities of Ph Negative ALL - Part XIII
5.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge